Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Clinical trial NCT03657160 · COMPLETED
Trial details
- NCT number
- NCT03657160
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-06
- Primary completion
- 2022-02-07
- Enrollment
- 343
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.